News Virgin Pulse eyes $3bn merger with HealthComp Digital health and wellness company Virgin Pulse has said it plans to merge with HealthComp, a health benefits administrator, in a $3 billion transaction that would create
News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face